NAMSNewAmsterdam Pharma Company N.V.
Is it growing?
Growth is fading: revenue shrinking (−89% year on year) and operating margin narrowing (−55695.6 points).
Trailing-twelve-month revenue vs a year earlier, from the company's own filings.
Trailing-twelve-month operating margin, -56426.9% now against -731.2% a year earlier.
All from SEC EDGAR, as of Jun 30, 2026.
Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.
Is NAMS growing?
NewAmsterdam Pharma Company N.V.'s revenue has shrunk 40% a year over three years.
Revenue growth, 3-year annual rate · Biotechnology median +21% · shrinking · compounded from fiscal-year columns as filed
- Years of annual history on file
- 5
Years of annual history on file · FY2021 to FY2025, as filed
Details›
- Revenue FY2022
- $103M
- Revenue FY2023
- $14M
- Revenue FY2024
- $46M
- Revenue FY2025
- $23M
Annual income statements as filed with the SEC.